----

| PENNSYLVANIA                                                  |         | 23-2795613                          |
|---------------------------------------------------------------|--------------|-------------------------------------|
| (State or other jurisdiction ofincorporation or organization) |         | (I.R.S. EmployerIdentification No.) |
|                                                          |         |                                |
| 317 Wekiva Springs Road, #200Longwood, Florida                |         | 32779(Zip Code)                     |
| (Address of principal executive offices)                      |    |                                |

----

| Large accelerated filer  ̈                                                              | Accelerated filer  ̈    |
|---------------------------------------------------------------------------------------------|-----------------------------|
|                                                                                        |                        |
| Non-accelerated filer    ̈ (Do not check if a smaller reporting company) | Smaller reporting company x |

| Number of Shares of Common StockOutstanding on May 16, 2011 |  162,074,026 |
|-------------------------------------------------------------|-------------------|

----

|   |         |                                                                                                 |         | Page   |
|--------|--------------|------------------------------------------------------------------------------------------------------|--------------|--------|
| ITEM 1 |         | Financial Statements.                                                                                |         |   |
|   |         |                                                                                                 |         |   |
|   |         | Consolidated Balance Sheets at March 31, 2011 (unaudited) and December 31, 2010                      |         | 3      |
|   |         |                                                                                                 |         |   |
|   |         | Consolidated Statements of Income (unaudited) for the three months ended March 31, 2011 and 2010     |         | 4      |
|   |         |                                                                                                 |         |   |
|   |         | Consolidated Statements of Cash Flows (unaudited) for the three months ended March 31, 2011 and 2010 |         | 5-6    |
|   |         |                                                                                                 |         |   |
|   |    | Notes to Consolidated Financial Statements                                                           |    | 7-9    |

----

|                                                                                                                                                                                                                                                                                                                                             |   |                                |        |   |                        |   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------|-------------|--------|-----------------------------|--------|
|                                                                                                                                                                                                                                                                                                                                             |   |                                |        |   |                        |   |
|                                                                                                                                                                                                                                                                                                                                             |   | (Unaudited)March 31, 2011 |        |   | December 31, 2010 |   |
| ASSETS                                                                                                                                                                                                                                                                                                                                           |   |                                |        |   |                        |   |
| Current Assets                                                                                                                                                                                                                                                                                                                                   |   |                                |        |   |                        |   |
| Cash and cash equivalents                                                                                                                                                                                                                                                                                                                        |   | $                                   | 227,073     |   |                        | $      | 429,299 |   |
| Accounts receivable                                                                                                                                                                                                                                                                                                                              |   |                                | 397,220     |   |                        |   | 404,624 |   |
| Inventory                                                                                                                                                                                                                                                                                                                                        |   |                                | 338,393     |   |                        |   | 223,697 |   |
| Prepaid expenses                                                                                                                                                                                                                                                                                                                                 |   |                                | 261,329     |   |                        |   | 243,244 |   |
| Total current assets                                                                                                                                                                                                                                                                                                                             |   |                                | 1,224,014   |   |                        |   | 1,300,864 |   |
|                                                                                                                                                                                                                                                                                                                                             |   |                                |        |   |                        |   |   |   |
| Property and equipment, net                                                                                                                                                                                                                                                                                                                      |   |                                | 175,383     |   |                        |   | 205,163 |   |
| Acquired Intangible Assets, net                                                                                                                                                                                                                                                                                                                  |   |                                | 271,846     |   |                        |   | 279,159 |   |
| Other assets                                                                                                                                                                                                                                                                                                                                     |   |                                | 2,540       |   |                        |   | 0 |   |
| Total assets                                                                                                                                                                                                                                                                                                                                     |   | $                                   | 1,673,784   |   |                        | $      | 1,785,186 |   |
|                                                                                                                                                                                                                                                                                                                                             |   |                                |        |   |                        |   |   |   |
| LIABILITIES                                                                                                                                                                                                                                                                                                                                      |   |                                |        |   |                        |   |   |   |
|                                                                                                                                                                                                                                                                                                                                             |   |                                |        |   |                        |   |   |   |
| Current maturity of long-term debt                                                                                                                                                                                                                                                                                                               |   | $                                   | 12,414      |   |                        | $      | 27,503 |   |
| Accounts payable and accrued expenses                                                                                                                                                                                                                                                                                                            |   |                                | 1,326,570   |   |                        |   | 1,292,480 |   |
| Accrued compensation                                                                                                                                                                                                                                                                                                                             |   |                                | 17,300      |   |                        |   | 146,600 |   |
| Deferred revenue                                                                                                                                                                                                                                                                                                                                 |   |                                | 275,341     |   |                        |   | 254,668 |   |
| Loans payable                                                                                                                                                                                                                                                                                                                                    |   |                                | 10,000      |   |                        |   | 10,000 |   |
| Total current liabilities                                                                                                                                                                                                                                                                                                                        |   |                                | 1,641,625   |   |                        |   | 1,731,250 |   |
|                                                                                                                                                                                                                                                                                                                                             |   |                                |        |   |                        |   |   |   |
| Convertible promissory notes payable, net of issuance of debt and stock conversion discounts                                                                                                                                                                                                                                                     |   |                                | 965,576     |   |                        |   | 951,503 |   |
| Total liabilities                                                                                                                                                                                                                                                                                                                                |   | $                                   | 2,607,201   |   |                        | $      | 2,682,754 |   |
| SHAREHOLDERS’ EQUITY (DEFICIENCY)                                                                                                                                                                                                                                                                                                          |   |                                |        |   |                        |   |   |   |
| Common stock, $.01 par value, 250,000,000 shares authorized as of March 31, 2011 and December 31, 2010; 164,933,185 shares and 155,373,185 shares issued as of March 31, 2011 and December 31, 2010, respectively;160,574,026  shares and 151,014,026 shares outstanding as of March 31, 2011 and December 31, 2010, respectively |   |                                | 1,649,332   |   |                        |   | 1,553,732 |   |
| Additional paid in capital                                                                                                                                                                                                                                                                                                                       |   |                                | 15,188,113  |   |                        |   | 14,863,493 |   |
| Stock warrants                                                                                                                                                                                                                                                                                                                                   |   |                                | 3,798,467   |   |                        |   | 3,686,077 |   |
| Accumulated deficit                                                                                                                                                                                                                                                                                                                              |   |                                | (20,017,094 | )      |                        |   | (20,448,635 | ) |
| Treasury stock, 4,359,169 shares as of March 31, 2011 and December 31, 2009, at cost                                                                                                                                                                                                                                                             |   |                                | (552,235    | )      |                        |   | (552,235 | ) |
| Total shareholders’ equity (deficiency)                                                                                                                                                                                                                                                                                                    |   |                                | (933,417    | )      |                        |   | (897,568 | ) |
| Total liabilities and shareholders’ equity (deficiency)                                                                                                                                                                                                                                                                                    |   | $                                   | 1,673,784   |   |                        | $      | 1,785,186 |   |

----

|                                                               |   |   |        |   |   |   |
|--------------------------------------------------------------------|--------|--------|-------------|--------|--------|--------|
|                                                               |   |   |        |   |   |   |
| Three months ended March 31,                   |   | 2011   |        |   | 2010   |   |
|                                                               |   |   |        |   |   |   |
| REVENUE                                                            |   | $      | 1,400,187   |   |   | $      | 2,221,111 |   |
|                                                               |   |   |        |   |   |   |   |   |
| COSTS OF GOODS SOLD                                                |   |   | 500,408     |   |   |   | 851,078 |   |
|                                                               |   |   |        |   |   |   |   |   |
| GROSS PROFIT                                                       |   |   | 899,779     |   |   |   | 1,370,033 |   |
|                                                               |   |   |        |   |   |   |   |   |
| EXPENSES                                                           |   |   |        |   |   |   |   |   |
| Selling, general and administrative                                |   |   | 1,378,806   |   |   |   | 1,815,582 |   |
| Research and development                                           |   |   | 9,024       |   |   |   | 968 |   |
|                                                               |   |   | 1,387,830   |   |   |   | 1,816,550 |   |
|                                                               |   |   |        |   |   |   |   |   |
| OPERATING LOSS                                                     |   |   | (488,051    | )      |   |   | (446,517 | ) |
|                                                               |   |   |        |   |   |   |   |   |
| OTHER EXPENSES                                                     |   |   |        |   |   |   |   |   |
| Amortization and depreciation                                      |   |   | 38,783      |   |   |   | 37,964 |   |
| Interest expense                                                   |   |   | 41,625      |   |   |   | 36,321 |   |
|                                                               |   |   |        |   |   |   |   |   |
|                                                               |   |   | 80,408      |   |   |   | 74,285 |   |
|                                                               |   |   |        |   |   |   |   |   |
| NET LOSS BEFORE PROVISION FOR INCOME TAXES                         |   |   | (568,459    | )      |   |   | (520,802 | ) |
|                                                               |   |   |        |   |   |   |   |   |
| PROVISION FOR INCOME TAXES                                         |   |   | 0           |   |   |   | 0 |   |
|                                                               |   |   |        |   |   |   |   |   |
| NET LOSS                                                           |   | $      | (568,459    | )      |   | $      | (520,802 | ) |
|                                                               |   |   |        |   |   |   |   |   |
| NET LOSS PER SHARE, BASIC & DILUTED                            |   | $      | (0.004      | )      |   | $      | (0.004 | ) |
|                                                               |   |   |        |   |   |   |   |   |
| Weighted average common shares and diluted potential common shares |   |   | 157,145,518 |   |   |   | 119,146,695 |   |

----

|                                                                       |   |   |     |   |   |   |
|----------------------------------------------------------------------------|--------|--------|----------|--------|--------|--------|
|                                                                       |   |   |     |   |   |   |
| Three months ended March 31                            |   | 2011   |     |   | 2010   |   |
|                                                                       |   |   |     |   |   |   |
| CASH FLOWS FROM OPERATING ACTIVITIES                                       |   |   |     |   |   |   |
| Net loss                                                                   |   | $      | (568,459 | )      |   | $      | (520,802 | ) |
| Adjustments to reconcile net loss to net cash used by operating activities |   |   |     |   |   |   |   |   |
| Depreciation and amortization                                              |   |   | 38,783   |   |   |   | 37,964 |   |
| Amortization of discounts on loans payable                                 |   |   | 14,073   |   |   |   | 14,621 |   |
| Common stock issued for services                                           |   |   | 27,000   |   |   |   | 0 |   |
| Fair value of options granted for services                                 |   |   | 62,330   |   |   |   | 25,000 |   |
| Changes in operating assets and liabilities                                |   |   |     |   |   |   |   |   |
| Accounts receivable                                                        |   |   | 7,404    |   |   |   | (46,181 | ) |
| Inventory                                                                  |   |   | (114,696 | )      |   |   | 152,508 |   |
| Prepaid expenses                                                           |   |   | (18,085  | )      |   |   | 8,915 |   |
| Other assets                                                               |   |   | (2,540   | )      |   |   | 0 |   |
| Accounts payable and accrued expenses                                      |   |   | (34,090  | )      |   |   | 112,719 |   |
| Accrued compensation                                                       |   |   | (39,300  | )      |   |   | 68,627 |   |
| Deferred revenue                                                           |   |   | 20,673   |   |   |   | 34,873 |   |
|                                                                       |   |   |     |   |   |   |   |   |
| Net cash used in operating activities                                      |   |   | (538,727 | )      |   |   | (109,881 | ) |
|                                                                       |   |   |     |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES                                       |   |   |     |   |   |   |   |   |
| Capital expenditures                                                       |   |   | (1,690   | )      |   |   | (23,570 | ) |
| Patent acquisition costs                                                   |   |   | 0        |   |   |   | 0 |   |
|                                                                       |   |   |     |   |   |   |   |   |
| Net cash used in investing activities                                      |   |   | (1,690   | )      |   |   | (23,570 | ) |
|                                                                       |   |   |     |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES                                       |   |   |     |   |   |   |   |   |
|                                                                       |   |   |     |   |   |   |   |   |
| Proceeds from issuance of common stock and warrants, net                   |   |   | 373,000  |   |   |   | 245,000 |   |
| Principal payments on note payable                                         |   |   | (15,089  | )      |   |   | (21,497 | ) |
| Commissions paid for fundraising costs                                     |   |   | (19,720  | )      |   |   | (17,836 | ) |
|                                                                       |   |   |     |   |   |   |   |   |
| Net cash provided by financing activities                                  |   |   | 338,191  |   |   |   | 205,667 |   |

----

|                                                |   |   |     |   |   |   |
|-----------------------------------------------------|--------|--------|----------|--------|--------|--------|
|                                                |   |   |     |   |   |   |
| Three months ended March 31     |   | 2011   |     |   | 2010   |   |
|                                                |   |   |     |   |   |   |
| NET INCREASE(DECREASE) IN CASH AND CASH EQUIVALENTS |   |   | (202,226 | )      |   |   | 72,216 |   |
|                                                |   |   |     |   |   |   |   |   |
| Cash and cash equivalents, beginning of period      |   |   | 429,299  |   |   |   | 196,857 |   |
|                                                |   |   |     |   |   |   |   |   |
| Cash and cash equivalents, end of period            |   | $      | 227,073  |   |   | $      | 269,073 |   |
|                                                |   |   |     |   |   |   |   |   |
| SUPPLEMENTAL CASH FLOW INFORMATION                  |   |   |     |   |   |   |   |   |
| Cash paid for interest                              |   | $      | 5,456    |   |   | $      | 5,926 |   |
|                                                |   |   |     |   |   |   |   |   |
| Non-cash investing and financing transactions:      |   |   |     |   |   |   |   |   |
| Stock warrants granted for services                 |   | $      | 62,330   |   |   | $      | 51,500 |   |
| Stock warrants granted for fundraising              |   | $      | 50,000   |   |   | $      | 223,653 |   |
| Common stock issued for services                    |   | $      | 27,000   |   |   | $      | 15,000 |   |

----

|                                  |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                  |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1 – DESCRIPTION OF ORGANIZATION |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                                  |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                                  |   | GeneLink, Inc. (the “Company”) and its subsidiaries, Dermagenetics, Inc., GeneWize Life Sciences, Inc. and Helix Health Solutions LLC operate in Florida.  The Company was organized under the laws of the Commonwealth of Pennsylvania and Dermagenetics, Inc. and GeneWize Life Sciences, Inc. were organized under the laws of the State of Delaware.  Helix Health Solutions, LLC was organized under the laws of the State of Florida. The Company is the successor to a Delaware corporation organized under the same name on September 21, 1994.  The Company’s offices are located in Longwood, Florida. The Company was founded in response to the information being generated in the field of human molecular genetics.  Scientists are discovering an increasing number of connections between genes and specific adverse health conditions or physical attributes and tendencies.  The growth of scientific knowledge in this area has been accelerating as a direct result of the National Institutes of Health Genome Project. On May 1, 2007, the Company received a U.S. patent for its proprietary method for assessing skin health in humans. The Company has also developed proprietary SNP-based genetic profiles named GeneLink Nutragenetic ProfileTM and Dermagenetics® profiles.  These profiles provide a means of assessing an individual's inherent genetic capacity to combat such conditions as oxidative stress and other important selected areas of physiologic health. The profiles, for example, can measure a person's potential to efficiently control oxygen free radical damage, eliminate hydrogen peroxide, protect and repair oxidized phospholipids and destroy harmful environmental compounds.  The Company's profile assessment enables nutritional and skin care companies and health care professionals to recommend a specific and targeted regime of antioxidant vitamins, nutrients or skin care formulations that have been specifically designed to compensate for identified deficiencies. On August 1, 2008, GeneWize Life Sciences, Inc., held its grand opening launch conference with over 1,600 participants from around the country.  GeneWize is the first direct selling company to focus exclusively on marketing nutritional supplements and skin care products specifically tailored to an individual’s genetic makeup.  Genetic assessment results drive an analysis that generates a nutritional or skin assessment linked to a proprietary titration- matrix custom recipe for each customer. In order to help compensate for any anticipated need for additional supplementation, genetically-indicated ingredients and nutrients (SNPboostTM, or “snip boosts”) are blended into a comprehensive base formulation. Thus, each customer’s product is individually custom manufactured each month. |

----

|                            |         | GeneWize’s foundational product offerings consist of its GeneWize Me Made ExclusivelyTM Nutrition System and its Me Made ExclusivelyTM Skin Serum.  The Me Made Exclusively TM Nutrition System and Me Made ExclusivelyTM Skin Serum are the first systems of personalized nutritional supplements and skin products manufacturing based on GeneLink’s genetic testing.  GeneLink’s patented pending assessments, such as GeneLink Healthy Aging AssessmentTM and Oxidative Stress, form the foundation science for GeneWize’s proprietary solutions.  Genetic assessment results drive a proprietary formulation with an assessment report linked to an individual “titration matrix.”  In order to help compensate for any predicted deficiencies, “genetically selected ingredients” (SNPboostsTM, or “snip boosts”) are blended into an individual nutritional or skin formulation.  Thus, each product is individually manufactured for just that customer. GeneWize, as a direct selling company, offers customers the opportunity to participate in selling and distributing the products to others and receive compensation for doing so.  These independent marketing Affiliates must agree to and comply with the company’s policies related to sales and distribution of product, particularly as it relates to product claims or, in the case of recruiting other affiliates, income potential.  In return for creating sales and complying with appropriate policies and regulations, GeneWize provides commissions and incentives.  It also provides internet ordering sites, business management tools, marketing materials, training and events in support of these affiliates. |
|---------------------------------|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            |         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 2 – BASIS OF PRESENTATION |    | The accompanying unaudited consolidated financial statements have been prepared by the Company in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X relating to interim financial statements.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements and should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report on Form 10-K of GeneLink, Inc. and Subsidiaries for the year ended December 31, 2010. In the opinion of management, all adjustments (consisting of normal recurring accruals) necessary to present fairly the information set forth in the accompanying consolidated financial statements have been included.  The results reported in these consolidated financial statements for the three-month period ended March 31, 2011 should not be regarded as necessarily indicative of results that may be expected for the year ended December 31, 2011.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

----

| 3– STOCKHOLDERS' EQUITY TRANSACTIONS AND CONVERTIBLE SECURED PROMISSORY NOTES |         | During the three months ended March 31, 2011, the Company sold 8,760,000 shares of restricted Common Stock of the Company at an exercise price of $0.05 per share pursuant to a Confidential Private Offering Memorandum, and received an aggregate gross amount of $438,000 In connection with the above offering, the Company incurred a total of $19,720 in placement fees and expenses and issued warrants to acquire 493,000 shares of Common Stock at an exercise price of $0.05 per share to First Equity Capital Securities, Inc., as placement agent, in connection with the sale of some of these units. Kenneth R. Levine, a holder of more than five percent of the equity securities of the Company and a member of the Company’s Scientific Advisory Board, is an officer and owner of First Equity Capital Securities, Inc. |
|-------------------------------------------------------------------------------------|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                |         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 4-SUBSEQUENT EVENT                                                                  |    | From April 1, 2011 through the date of this filing, the Company sold an additional 1,500,000 shares of restricted Common Stock of the Company at an exercise price of $0.05 per share pursuant to a Confidential Private Offering Memorandum, and received an aggregate amount of $75,000.00.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

----

----

----

----

----

| Item 3 | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
|--------|------------------------------------------------------------|

| Item 4. | CONTROLS AND PROCEDURES |
|---------|-------------------------|

----

| Item 1 |         | LEGAL PROCEEDINGS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|        |         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|        |    | By Order and Opinion dated May 5, 2009 and received on May 8, 2009, the Court of Common Pleas of Pennsylvania, Philadelphia County, dismissed an action brought by Mr. DePhillipo and his wife (the "Action") in August 2008.  In the Action, the DePhillipos alleged that the Company, as well as GeneWize and several of the Company's directors, officers and representatives, defrauded them into settling a lawsuit previously commenced by Mr. DePhillipo against the Company in the Superior Court of New Jersey, Atlantic County (the "New Jersey Action").  In the Action, the DePhillipos sought the return of 3,953,000 shares of the Company's common stock sold to the Company pursuant to the settlement, allegedly worth approximately $20 million based upon an alleged value of $5.00 per share. Via its Order and Opinion, the Court dismissed the Action, concluding that the DePhillipos' claims were not viable.  The Court also determined that it lacked jurisdiction over the Company's counsel in the New Jersey Action as well as the Company's advisors. The DePhillipo’s filed a Notice of Appeal with respect to the Order and Opinion on May 14, 2009. On September 13, 2010, the Court of Common Pleas of Pennsylvania, Philadelphia County, affirmed the dismissal of a complaint filed by the Company’s former Chief Executive Officer and President, John DePhillipo, and his wife against the Company, GeneWize and several of the Company’s offices, directors and advisors. On October 13, 2010, the DePhillipos filed a Petition for Allowance of Appeal with the Pennsylvania Supreme Court in response to which the GeneLink, GeneWize and all other respondents have filed an Answer in Opposition to Petition for Allowance of Appeal. By Order dated March 30, 2011, the Supreme Court of Pennsylvania denied the DePhillipos’ Petition for Allowance of Appeal. In September 2009, the Company brought action against two prior law firms, alleging that their failure to timely provide legal services and make or authorize required filings caused the Company to lose valuable Japanese and U.S. patent rights.  In March 2010, the Company voluntarily dismissed one of the law firms from the action.  In August 2010, the remaining law firm filed a counterclaim for alleged unpaid legal fees owed to it by the Company. |

----

| Item 2  | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
|-------------------|-------------------------------------------------------------|

| Date                      |   | $ of Investment |    |   | Number of Shares Issued |   |      | Number of Investors |   |
|---------------------------|--------|---------------------------|---------|--------|----------------------------------------|--------|-----------|-------------------------------|--------|
| 1/18/11                   |   | $                         | 115,000 |   |                                   |   | 2,300,000 |                          |   |   | 2 |   |
| 1/20/11                   |   |                      | 25,000  |   |                                   |   | 500,000   |                          |   |   | 1 |   |
| 1/21/11                   |   |                      | 40,000  |   |                                   |   | 800,000   |                          |   |   | 1 |   |
| 1/24/11    |   |                      | 15,000  |   |                                   |   | 300,000   |                          |   |   | 2 |   |
| 1/25/11                   |   |                      | 30,000  |   |                                   |   | 600,000   |                          |   |   | 2 |   |
| 1/27/11                   |   |                      | 78,000  |   |                                   |   | 1,560,000 |                          |   |   | 3 |   |
| 1/28/11                   |   |                      | 55,000  |   |                                   |   | 1,100,000 |                          |   |   | 3 |   |
| 1/31/11                   |   |                      | 40,000  |   |                                   |   | 800,000   |                          |   |   | 2 |   |
| 2/4/11                    |   |                      | 20,000  |   |                                   |   | 400,000   |                          |   |   | 1 |   |
| 2/5/11                    |   |                      | 10,000  |   |                                   |   | 200,000   |                          |   |   | 1 |   |
| 3/2/11                    |   |                      | 10,000  |   |                                   |   | 200,000   |                          |   |   | 1 |   |
|                      |   |                      |    |   |                                   |   |      |                          |   |   |   |   |
| Total                     |   | $                         | 438,000 |   |                                   |   | 8,760,000 |                          |   |   | 19 |   |

| Item 3  | DEFAULTS UPON SENIOR SECURITIES |
|-------------------|---------------------------------|

| Item 4  | (REMOVED AND RESERVED) |
|-------------------|------------------------|

| Item 5  | OTHER INFORMATION |
|-------------------|-------------------|

| Item 6  | EXHIBITS |
|-------------------|----------|

| Exhibit No. |   | Description                                                                                                                       |
|-------------|--------|-----------------------------------------------------------------------------------------------------------------------------------|
|        |   |                                                                                                                              |
| 31.1        |   | Certificate of the Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1        |   | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.           |

----

| Date: May 12, 2011 | By:    | s/ Bernard L. Kasten, Jr., M.D.                                                     |
|--------------------|--------|-------------------------------------------------------------------------------------|
|               |   | Bernard L. Kasten, Jr., M.D., ChiefExecutive Officer and Principal FinancialOfficer |

----